Tysabri Progressive Multifocal Leukoencephalopathy Attorney: Statute of Limitations for Tysabri in Michigan
Latest update (2026-07)
Tysabri (natalizumab) PML injury claims continue to be evaluated based on individual monitoring and diagnosis records. [source]
From General Health Information to Targeted Risk Awareness
For decades, the domain of general health and science information has served as a foundational resource for public understanding of medical treatments and their potential risks. Within this broad context, the dissemination of knowledge about pharmaceutical interventions has evolved from simple awareness campaigns to more nuanced discussions of patient safety and long-term outcomes. This legacy of informed public discourse now intersects with a more specialized area of concern: the occupational and environmental exposures that may arise from the use of specific biologic therapies. In the realm of mass production, particularly within healthcare and pharmaceutical manufacturing settings, workers and patients alike may encounter substances that carry distinct risk profiles. One such therapy is Tysabri, a medication used in the management of certain chronic conditions. Over time, clinical experience has identified a rare but serious association between Tysabri exposure and the development of progressive multifocal leukoencephalopathy (PML), a viral infection of the brain. This recognition has shifted the focus from general health education to a targeted examination of exposure pathways, especially for individuals who may have received the drug in a clinical or occupational capacity. As a result, the conversation now pivots from broad health literacy to a specific legal and medical question: for those in Michigan who have been exposed to Tysabri and subsequently diagnosed with PML, understanding the applicable statute of limitations becomes critical. This transition underscores the need for precise, context-aware guidance that bridges general health knowledge with the realities of exposure-related liability.
Medical Evidence Linking Tysabri to PML
Tysabri (natalizumab) is a biologic therapy approved as monotherapy for relapsing forms of multiple sclerosis and for Crohn’s disease. Its use carries a well-documented risk of progressive multifocal leukoencephalopathy (PML), a severe opportunistic brain infection caused by the JC virus. For patients in Michigan who have developed PML after Tysabri treatment, understanding the medical evidence and legal time limits is critical. PML is an infection of the brain’s white matter that typically occurs only in immunocompromised individuals. In Tysabri-treated patients, PML usually leads to death or severe disability (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information identifies three key risk factors: the presence of anti-JCV antibodies, longer treatment duration (especially beyond two years), and prior use of immunosuppressants (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). These factors should be considered when initiating or continuing Tysabri therapy (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and vision changes. The FDA Adverse Event Reporting System (FAERS) data for Tysabri show frequent reports of fatigue, multiple sclerosis relapse, headache, gait disturbance, balance disorder, memory impairment, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). While these symptoms overlap with multiple sclerosis itself, any new or worsening neurological symptom in a Tysabri-treated patient should prompt immediate evaluation for PML.
Mechanism of Action and Risk Factors
Tysabri works by binding to alpha-4 integrins on immune cells, preventing their migration into the brain. This reduces inflammation in multiple sclerosis but also impairs immune surveillance against JC virus. The resulting immunosuppression in the central nervous system allows JC virus to reactivate and cause PML. The boxed warning states that Tysabri increases the risk of PML, an opportunistic viral infection of the brain (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The label further notes that PML typically only occurs in patients who are immunocompromised (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The prescribing information includes a boxed warning that clearly states Tysabri increases PML risk and that healthcare professionals should monitor patients for any new sign or symptom suggestive of PML, withholding dosing immediately at the first sign (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). The drug is also available only through a restricted distribution program called the TOUCH Prescribing Program (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Despite these warnings, questions may arise about whether patients and physicians were adequately informed about the magnitude of risk, especially for those with longer treatment durations or prior immunosuppressant use.
Statute of Limitations for Tysabri Claims in Michigan
PML can develop months to years after starting Tysabri. The risk increases with longer treatment duration, particularly beyond two years (https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=c5fdde91-1989-4dd2-9129-4f3323ea2962). Once PML develops, the disease progresses rapidly, often leading to severe disability or death. The latency period between Tysabri exposure and PML diagnosis can complicate legal claims, as the statute of limitations may begin running from the date of injury or from when the injury was discovered. In Michigan, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For wrongful death claims, the limit is generally three years from the date of death. Because PML may not be diagnosed immediately after symptoms appear, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm. Patients and families should consult with an attorney promptly to preserve their legal rights.
Legal Considerations for Affected Patients
Patients in Michigan who developed PML after Tysabri treatment may have legal claims based on inadequate warnings or failure to monitor. An attorney can review medical records to determine whether the prescribing physician followed the TOUCH program requirements and whether the patient’s risk factors were properly assessed. The attorney will also need to establish the timeline between Tysabri exposure and PML diagnosis, as well as the extent of disability or death. Given the severity of PML, damages may include medical expenses, lost income, pain and suffering, and, in fatal cases, wrongful death damages. Tysabri carries a known risk of PML, with identifiable risk factors including anti-JCV antibodies, treatment duration beyond two years, and prior immunosuppressant use. The prescribing information includes a boxed warning and mandates monitoring, but affected patients in Michigan should be aware of the three-year statute of limitations for personal injury claims. Prompt legal consultation is essential to evaluate the adequacy of warnings and the specific circumstances of the injury.
Important Notice
This page is for educational and informational purposes only. It does not provide medical diagnosis, treatment, or legal advice. Consult licensed clinicians and qualified attorneys for case-specific decisions.
Frequently Asked Questions
What is the statute of limitations for Tysabri-related PML claims in Michigan?
In Michigan, the statute of limitations for personal injury claims, including those related to prescription drug injuries, is generally three years from the date of injury or from when the injury was discovered or should have been discovered. For wrongful death claims, the limit is generally three years from the date of death. Because PML may not be diagnosed immediately, the discovery rule may apply, meaning the clock starts when the patient knew or reasonably should have known that Tysabri caused the harm.
What are the risk factors for developing PML from Tysabri?
What symptoms should prompt evaluation for PML in Tysabri-treated patients?
Clinical presentation of PML can include progressive neurological deficits such as weakness, gait disturbance, cognitive impairment, and vision changes. The FDA Adverse Event Reporting System (FAERS) data for Tysabri show frequent reports of fatigue, multiple sclerosis relapse, headache, gait disturbance, balance disorder, memory impairment, and cognitive disorder (https://api.fda.gov/drug/event.json?search=patient.drug.medicinalproduct:TYSABRI). Any new or worsening neurological symptom should prompt immediate evaluation.
Does submitting information create an attorney-client relationship?
No. Submission requests an initial records screening only and does not create an attorney-client relationship.
This page is for educational and informational purposes only and is not medical or legal advice. Consult a licensed professional for case-specific guidance.